Cue Biopharma, Inc.
Cue Biopharma, Inc. scores highest on Nitro (45) and lowest on Price (1). Its PosiPenta is 27.08 out of 100, weaker than most similar companies.
On the Penta Grid this week, Cue Biopharma, Inc. is Grid #796 of 837 in the Healthcare sector in United States, and Grid #3,747 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Cue Biopharma, Inc. | 27.08 | 1 | 41 | 45 | 8 | 41 |
| Outlook Therapeutics, Inc. | 49.33 | 0 | 64 | 30 | 96 | 57 |
| AN2 Therapeutics, Inc. | 47.49 | 32 | 43 | 54 | 68 | 40 |
| Atrium Therapeutics, Inc. | 41.91 | 44 | 15 | 31 | 77 | 43 |
| Quanterix Corporation | 43.19 | 45 | 41 | 34 | 49 | 48 |
| WW International, Inc. | 53.66 | 94 | 53 | 37 | 36 | 48 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.56 |
| P/B ratio | 52.55 |
EEarnings
| Trailing EPS | ₹-2802.62 |
| Forward EPS | ₹-45.46 |
NNitro
| Price | 1582.69 |
| 52-week high | 4309.53 |
| 52-week low | 471.68 |
| Fall from 52-week high | 63.3% |
TTorque
| Return on equity (ROE) | -1603.48% |
| Debt-to-equity | 1.33 |
AAnchor
| Beta (price swings) | 2.63 |
| Market cap | ₹1,149 Cr |
| Insider holding | 15.05% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Cue Biopharma, Inc.'s PosiPenta score?
Cue Biopharma, Inc.'s PosiPenta is 27.08 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Cue Biopharma, Inc. stand on the Penta Grid?
On the Penta Grid this week, Cue Biopharma, Inc. is Grid #796 of 837 in the Healthcare sector in United States, and Grid #3,747 of 4,000 in United States.
Which PosiPenta pillar is strongest for Cue Biopharma, Inc.?
Nitro (momentum), with a score of 45 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Cue Biopharma, Inc.?
Price (valuation), with a score of 1 out of 100: much weaker than most similar companies.
Has Cue Biopharma, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.56 points, from 24.52 to 27.08.
PositoAI is for research and education only and is not investment advice.